Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

4 hours ago 1
Read Entire Article
  1. Homepage
  2. Finance
  3. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Related

Heidrick & Struggles Q1 2025 slides: revenue growth across all segments, strong cash position

Heidrick & Struggles Q1 2025 slides: revenue growth across a...

13 minutes ago 0
Realty Income Q1 2025 slides: Revenue exceeds forecast while maintaining AFFO guidance

Realty Income Q1 2025 slides: Revenue exceeds forecast while...

13 minutes ago 0
Travere therapeutics CEO sells $398k in stock

Travere therapeutics CEO sells $398k in stock

13 minutes ago 0

Trending

1. trump administration
2. mother's day gifts
3. nuggets
4. watson tv show
5. anthony bourdain
6. xander bogaerts
7. cm punk
8. andrew weissmann
9. pete alonso
10. devin williams

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

3 months ago 154
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

2 months ago 121
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

4 months ago 117
TOUS les JOURS Opens in Henderson!

TOUS les JOURS Opens in Henderson!

3 months ago 90
Sole mates: Find the perfect shoes for your fitness journey

Sole mates: Find the perfect shoes for your fitness journey

3 months ago 83
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved